The importance of left ventricular hypertrophy in human hypertension

Journal of Hypertension, Supplement

Volumn 16, Issue 7, 1998, Pages

  Kahan, Thomas ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

AIIRAs; Angiotensin II; Atenolol; Irbesartan; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GEOMETRY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN;

EID: 0031783044     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-1263.
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
3. Weber KT, Sun Y, Guarda E Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (the heart): relevance to hypertensive heart disease. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management New York: Raven Press Ltd; 1995. pp. 2203-2223.
4. Messerli FH. Pathophysiology of left ventricular hypertrophy. In: Messerli FH (editor): Left ventricular hypertrophy and its regression (2nd Edition). London: Science Press; 1996. pp. 2.1-2.15.
5. Rowlands DB, Glover DR, Ireland MA, McLeay RA, Stallard TJ, Watson RD, Littler WA. Assessment of left ventricular mass and its response to antihypertensive treatment. Lancet 1982; i:467-470.
6. Devereux R, Pickering TG, Harshfield GA. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983; 68:470-476.
7. Drayer JM, Weber MA, De Young JL. Blood pressure as a determinant of cardiac left ventricular mass. Arch Intern Med 1983; 143:90-92.
8. Kleinert HD, Harshfielf GA, Pickering TG, McLeay RA, Stallard TJ, Watson RD, et al. What is the value of home blood pressure measurement in patients with mild hypertension? Hypertension 1984; 6:574-578.
9. Prisant LM, Carr AA. Ambulatory blood pressure monitoring and echocardiographic left ventricular wall thickness and mass. Am J Hypertens 1990; 3:81-89.
10. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldirin F, Porcellati C. Orcadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528-536.
11. Radice M, Alli C, Avanzini F, Di Tullio M, Mariotti G, Taioli E, Zussino A. Index of left ventricular hypertrophy in adolescents genetically predisposed to the development of arterial hypertension. G Ital Cardiol 1985; 15:370-374.
12. Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet 1982; 78:951-956.
13. Messerli FH. Clinical determinants and consequences of left ventricular hypertrophy. Am J Med 1983; 75:51-56.
14. Lie JT, Hammond Pl. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988; 63:552-564.
15. Lernfelt B, Wikstrand J, Svanborg A, Landahl S. Aging and left ventricular function in elderly healthy people. Am J Cardiol 1991 ; 68:547-549.
16. Paciaroni E, Fraticelli A. Left ventricular hypertrophy: prevalence in older patients and management. Drugs Aging 1995; 6:301-311.
17. Schmieder RE, Messerli FH, Gravaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation 1988; 78:951-956.
18. Folkow B. Physiological aspects of hypertension. Physiol Rev 1982; 62:347-504.
19. Kaplan NM. Primary hypertension: natural history, special populations, and evaluation. In: Neal WW (editor): Clinical hypertension (6th Edition). Baltimore: Williams & Wilkins; 1994. pp. 109-143.
20. Östergren J, Isaksson H, Kahan T. Insulin sensitivity predicts the response to antihypertensive therapy: a substudy to CAPPP [abstract]. Am J Hypertension 1996; 9:167A.